The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease. Blenrep (belantamab mafodotin) has been ...

Researchers uncover corneal changes in multiple myeloma patients treated with belantamab mafodotin, revealing potential ...

As GSK weathers the storm of sinking vaccine sales and gears up for key launches in its specialty medicines sector, the ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...

You can reach Andrew on Signal at drewqjoseph.45. GSK’s blood cancer drug Blenrep won regulatory approval in the U.K. on Thursday, marking the medicine’s return to the market after it was ...

GSK (GSK) plc announced the authorization of Blenrep by the Medicines and Healthcare products Regulatory Agency. “In the UK, Blenrep is approved for the treatment of adults with multiple myeloma ...

GSK’s profit rose on better-than-expected performance of HIV, cancer and asthma treatments, offsetting lower vaccine demand ...

GSK (LSE:GSK) reported a significant improvement in its first-quarter earnings, with sales, net income, and earnings per ...

Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ETCompany ParticipantsConstantin Fest - Head of IREmma Walmsley - CEOLuke Miels ...

offsetting lower vaccine demand in the U.S. GSK plans to bring five new specialty medicines to market this year, including a comeback of previously withdrawn multiple myeloma treatment Blenrep ...